CAMBRIDGE, Mass., June 7 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) today announced that it will present at The Wall Street Analyst Forum - 17th Annual Analyst Conference on Wednesday, June 14, 2006, at 10:30 a.m. EDT. The analyst and investor conference is being held at the Princeton Club in New York City. A live webcast will be available online via the Investor Relations section of Biopure's web site at http://www.biopure.com or at http://www.investorcalendar.com/CEPage.asp?ID=104919 . An archive of the presentation will be available for at least two weeks.
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure® [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure plans to apply in Europe, in mid 2006, for regulatory approval of a proposed surgical anemia indication. The company is developing Hemopure for a potential indication in cardiovascular ischemia, in addition to supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. The company's veterinary product Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs.
Statements in this announcement that are not strictly historical are forward-looking statements. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, unexpected costs and expenses, delays and determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, and delays in or unpredictable outcomes of clinical trials. The company undertakes no obligation to release publicly the results of any revisions to these forward- looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Form 10-Q filed on March 13, 2006, which can be accessed in the EDGAR database at the SEC Web site, http://www.sec.gov. The content of this announcement does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.
Contact: Douglas Sayles Herb Lanzet (Investors) Biopure Corporation H.L. Lanzet Inc. (617) 234-6826 (212) 888-4570 IR@biopure.com lanzet@aol.com
Source: Biopure Corporation
